Almac Group Appoints Dr Alan Lamont as VP BD & Licensing

October 1, 2019

Craigavon, UK, 01 Oct 2019 – Almac Discovery, a member of the Almac Group, today announced the appointment of Dr Alan Lamont to the position of Vice President of BD & Licensing, reporting to Managing Director & President, Dr Stephen Barr.

Dr Lamont will assume overall responsibility for all commercial activities within Discovery including the evaluation, structuring, negotiation and due diligence of BD and Licensing opportunities, and providing commercial input into research and discovery strategy as part of the Discovery senior management team.

Alan is a well-respected, experienced senior Business Development executive with over 30 years employed in both pharmaceutical and biotech environments throughout the UK and US. He has held senior global roles including Executive Director, Global External R&D with Eli Lilly and, most recently, Senior BD Lead at Mundipharma International.

Combining a scientific background and qualification with strong business development and licensing experience, Alan is experienced in drug discovery, development and technology platforms.

Alan holds both a PhD in Immunology/Physiology from the Faculty of Medicine at University of Edinburgh and a BSc from Faculty of Science from University of Glasgow.

Dr Barr, commented on Alan’s appointment: “We are pleased to welcome Alan to our senior management team at Almac Discovery. With extensive experience in the pharma and biotech space, particularly within the BD and licensing space, his expertise, understanding and industry insight makes him the ideal choice to oversee this vital function. We very much look forward to working with him as we continue to expand globally.”


About Almac Discovery

Almac Discovery is a research driven oncology company dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to licence programmes early with a pharmaceutical partner for further development.

For more information, please visit or e-mail [email protected].

About Almac Group
A unique culture delivering exceptional solutions

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5600 highly skilled personnel across 18 facilities including Europe, the US and Asia.

The company has a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.

To keep up to date with latest news, follow Almac Group on Twitter and LinkedIn or visit


Back to news